<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991211</url>
  </required_header>
  <id_info>
    <org_study_id>NHL 1-2003</org_study_id>
    <nct_id>NCT00991211</nct_id>
  </id_info>
  <brief_title>Bendamustine Plus Rituximab Versus CHOP Plus Rituximab</brief_title>
  <official_title>Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study addresses the question if the first line therapy of low malignant and mantle cell
      lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus
      rituximab with regard to progression free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 4 agent chemotherapy (CTX) CHOP (cyclophosphamide, doxorubicin, vincristine prednisone)
      in combination with the monoclonal anti-CD20 antibody rituximab (CHOP-R) represents a
      standard CTX for the treatment of lymphomas of high or low malignancy. The combination of
      bendamustine and rituximab (B-R) is also highly effective with a more advantageous toxicity
      profile. If B-R could be shown to be non inferior to CHOP-R, this could improve the quality
      of life of the patient and possibly also the prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>observation 3 years or significant differences between two arms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination and comparison of remission rates, of toxicity, infectious complications, overall survival, EFS, TTNT, capacity of peripheral blood stem cell mobilization</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">549</enrollment>
  <condition>Non-Hodgkin Lymphomas</condition>
  <condition>Follicular Lymphomas</condition>
  <condition>Immunocytomas</condition>
  <condition>Lymphocytic Lymphomas</condition>
  <condition>Marginal Zone Lymphomas</condition>
  <arm_group>
    <arm_group_label>Bendamustine + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP + Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Comparison of Bendamustine + Rituximab with CHOP + Rituximab</description>
    <arm_group_label>Bendamustine + Rituximab</arm_group_label>
    <other_name>Ribomustin, Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy CHOP + Ritiximab</intervention_name>
    <description>Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy</description>
    <arm_group_label>CHOP + Rituximab</arm_group_label>
    <other_name>Endoxan(R), Cyclostin(R) = Cyclophosphamide</other_name>
    <other_name>Adriamycin(R) Doxorubicin</other_name>
    <other_name>Oncovin(R) Vincristine</other_name>
    <other_name>Prednison</other_name>
    <other_name>Rituxan(R), MabThera(R) = Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological verified CD20-positive B-Cell-Lymphomas of the following
             entities:

               -  Follicular lymphoma grade 1 and 2

               -  Immunocytoma and lymphoplasmocytic lymphoma

               -  Marginal zone lymphoma, nodal and generalised

               -  Mantle cell lymphoma

               -  lymphocytic lymphoma (CLL without leucaemic characteristics)

               -  non-specified/classified lymphomas of low malignancy

          -  No prior therapy with cytotoxics,interferon or monoclonal antibodies

          -  Need for therapy, except mantle cell lymphomas

          -  Stadium III or IV

          -  Written informed consent

          -  Performance status WHO 0-2

          -  Histology not older than 6 months

        Exclusion Criteria:

          -  Patients not establishing all above mentioned prerequisites

          -  Option of a primary, potential curative radiation therapy

          -  Pretreatment except a unique local delimited radiation (radiation fiel not expanding
             two adjacent lymph node regions

          -  Comorbidities excluding a study conform therapy:

               -  heart attack during the last 6 months

               -  severe, medicinal not adjustable hypertonia

               -  severe functional defects of the heart (NYHA III or IV)

               -  lung (WHO grade III or IV), liver or kidney (creatinine &gt; 2 mg/dl, GOT + GPT or
                  bilirubin 3 x ULN, except caused by lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Rummel, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Group of indolent Lymphom,as (StiL)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>StiL Head Office; Justus-Liebig-University</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stil-info.de</url>
    <description>Homepage of the Study group of indolent lymphomas (StiL)</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Jurgen Barth</investigator_full_name>
    <investigator_title>Study Group indolent Lymphomas (StiL)</investigator_title>
  </responsible_party>
  <keyword>Comparison</keyword>
  <keyword>Bendamustine + Rituximab</keyword>
  <keyword>CHOP + Rituximab</keyword>
  <keyword>Progression free survival</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

